At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Randomized Phase II Study of Paclitaxel With or Without the Anti-IGF-IR mAb Cixutumumab (IMC-A12) as Second Line Treatment for Patients With Metastatic Esophageal or GE Junction Cancer
In Brief
A Phase 2 clinical trial evaluating Cixutumumab, Laboratory Biomarker Analysis, and 2 other interventions for Metastatic Esophageal Adenocarcinoma and 7 related conditions. Active but no longer recruiting, targeting 94 participants across 232 sites.
Signals
Detailed Summary
This randomized phase II trial studies how well paclitaxel with or without cixutumumab works in treating patients with esophageal cancer or gastroesophageal junction cancer that has spread to other places in the body (metastatic). Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Cixutumumab may kill cancer cells by blocking the action of a protein needed for cancer cell growth. Giving paclitaxel with or without cixutumumab may kill more tumor cells.
Study Details
Timeline
Arms & Interventions
Patients receive paclitaxel IV over 1 hour on days 1, 8, and 15.
Patients receive cixutumumab IV over 1 hour on days 1 and 15, and paclitaxel as in Arm I.
Interventions
Given IV
Correlative studies
Given IV
Correlative studies